Table 2. List of All the Compounds, Including Repurposed Drugs, Discussed in the Text.
| compd | target | phase | clinical trial ID | refs |
|---|---|---|---|---|
| 1 | 3CLpro | preclinical | (40,51,52) | |
| 2 | 3CLpro | preclinical | (42) | |
| 3 | 3CLpro | preclinical | (35) | |
| 4 | 3CLpro | preclinical | (35) | |
| 5 | 3CLpro | preclinical | (55) | |
| 6 | 3CLpro | preclinical | (55) | |
| 7 (GC376) | 3CLpro | preclinical | (43,56,57,59,60) | |
| 8 | 3CLpro | preclinical | (71) | |
| 9 | 3CLpro | Ib | NCT04535167 | (72) |
| Boceprevir | 3CLpro | preclinicala | (47,59) | |
| Baicalein | 3CLpro | preclinicalb | (76) | |
| Baicalin | 3CLpro | preclinicalc | (76) | |
| 10 | 3CLpro | preclinical | ||
| 11 | PLpro | preclinical | (87) | |
| 12 | PLpro | preclinical | (87) | |
| Ebselen | 3CLpro PLpro | preclinicald | (40,88) | |
| 13 | PLpro | preclinical | (89) | |
| 14 | PLpro | preclinical | (89) | |
| 15 | PLpro | preclinical | (89) | |
| 16 | PLpro | preclinical | (89) | |
| 17 | PLpro | preclinical | (91,92) | |
| Remdesivir | RdRp | FDA approved12 | NCT04292899, NCT04280705 | (109,110) |
| Favipiravir | RdRp | IIIe | ChiCTR2000030254 | (135) |
| Galidesivir | RdRp | I | NCT03891420 | (141,142) |
| 18 (EIDD-2801) | RdRp | II | NCT04405570, NCT04405739 | (98,143−146) |
a
Marketed for HCV.
b
Phase II for influenza fever (NCT03830684).
c
Phase I as an ingredient of Moist Exposed Burn Ointment (MEBO) for the treatment of pain and re-epithelization (NCT03728244, NCT02737943).
d
Phase II for brain disorders.
e
Marketed for influenza virus infections.